Abstract:Arsenic compounds, including arsenic trioxide (As2O3) and arsenic sulfide (As4S4), have recently been shown to be effective in the treatment of acute promyelocytic leukemia (APL). In vitro, As2O3 exerts a dosedependent dual effect: it triggers apoptosis at relatively high concentrations (0.5 to 2.0 μmol/L) and induces partial differentiation at low concentrations (0.1 to 0.5 μmmol/L). The apoptosis-inducing effect is associated with the collapse of mitochondrial transmembrane potentials in a thiol-dependent manner, whereas the retinoic acid signaling is required for APL cell differentiation. As2O3 over a wide range of concentrations (0.1 to 2.0 μmol/L) induces degradation of PML-RARα as well as the wild-type PML and enhances the acetylation of histone, a process important for the transcriptional activation of genes. In vivo, As2O3 induces a high complete remission (CR) rate in patients with both primary and relapsed APL (around 85% to 90%). Side effects, such as skin reaction, gastrointestinal symptoms, electrocardiographic (EKG) changes, neuropathy, and liver dysfunction, are mild to moderate in relapsed patients, and severe hepatic lesions have been found in some primary cases. After CR obtained in relapsed patients, chemotherapy in combination with As2O3 as postremission therapy has yielded better survival than treatment with As2O3 alone. This is in line with the observation that remission induction with As2O3 is not sufficient in most cases to obtain a molecular remission as judged by reverse-transcriptase polymerase chain reaction for PML-RARα fusion transcripts. The in vivo effect of As2O3 seems to be related to the expression of APL-specific PML-RARα oncoprotein, and a synergistic effect between As2O3 and ATRA has been shown in the APL mouse model. Besides As2O3, other arsenic compounds such as As4S4 also show a therapeutic effect in APL. Because the toxic effects of arsenic treatment in primary APL need to be investigated further, we propose use of ATRA as a first-line drug for remission induction in primary APL, whereas As2O3 can be incorporated into multidrug postremission therapy or used as rescue for relapsed APL patients.

Arsenic in cancer therapy.

From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia.

How Acute Promyelocytic Leukaemia Revived Arsenic

Arsenic in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Current Status and Future Research Direction

Arsenic compounds: The wide application and mechanisms applied in acute promyelocytic leukemia and carcinogenic toxicology

When Poisons Cure: The Case of Arsenic in Acute Promyelocytic Leukemia

Arsenic Trioxide and Leukemia

Treatment of Acute Promyelocytic Leukemia with Arsenic Compounds: in Vitro and in Vivo Studies

Double-Edged Effects of Arsenic Compounds: Anticancer and Carcinogenic Effects

Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.

Arsenic trioxide, a therapeutic agent for APL.

Differentiation and apoptosis induction therapy in acute promyelocytic leukaemia

Expanding the Use of Arsenic Trioxide: Leukemias and Beyond.

Harness arsenic in medicine: current status of arsenicals and recent advances in drug delivery

Research progress on arsenic, arsenic-containing medicinal materials, and arsenic-containing preparations: clinical application, pharmacological effects, and toxicity

Arsenic induced epigenetic changes and relevance to treatment of acute promyelocytic leukemia and beyond

Arsenene: A Potential Therapeutic Agent for Acute Promyelocytic Leukaemia Cells by Acting on Nuclear Proteins

An Evidence-based Perspective of Arsenic Trioxide (As<sub>2</sub>O<sub>3</sub>) for Cancer Patients

Arsenic Binding To Rbcc Domain Modulates Oncogenic Pml-Rara And Wild-Type Pml As A Key Molecular Mechanism Of Arsenic Trioxide Treatment For Apl

Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide: Clinical and Basic Studies

Therapeutic Strategy of Arsenic Trioxide in the Fight Against Cancers and Other Diseases